Bemarituzumab
Bladder Transitional Cell Carcinoma
Explore 37 assets in Bladder Transitional Cell Carcinoma →Floatz Rating
CC44/100
Confidence
Indicative
Sponsor
Five Prime Therapeutics, Inc.
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
29Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02318329CT.gov Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bladder Transitional Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bemarituzumab (this asset) | Five Prime Therapeutics, Inc. | P1 | CC · 44 |
| Cis-Diamminedichloroplatinum Ii | Nagoya University | P3 | BB |
| Atezolizumab | KaliVir Immunotherapeutics | P3 | BB |
| Carboplatin | Jonsson Comprehensive Cancer Center | P2 | BB |
| Pembrolizumab | Fred Hutchinson Cancer Center | P3 | BB |
| Nivolumab | Nagoya University | P3 | BB |
| Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) | Fred Hutchinson Cancer Center | P2 | BB |
| Durvalumab | Alliance for Clinical Trials in Oncology | P3 | B |
| Adriamycin | University of Southern California | P2 | B |
+42 more in the Bladder Transitional Cell Carcinoma cohort
Other indications for Bemarituzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P2 | CC · 47 |
| Endometrial Carcinoma | — | P1/2 | CC · 44 |
| Cervical Cancer | — | P1/2 | CC · 44 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bemarituzumab in Bladder Transitional Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bemarituzumab-bladder-transitional-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →